Rosiglitazone
- Generic Name
- Rosiglitazone
- Brand Names
- Avandamet, Avandia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O3S
- CAS Number
- 122320-73-4
- Unique Ingredient Identifier
- 05V02F2KDG
- Background
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellula...
- Indication
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
The Use of Rosiglitazone to Treat Asthma
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2011-09-02
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 16
- Registration Number
- NCT00614874
- Locations
- 🇺🇸
Creighton University Medical Center, Department of Pulmonology and Critical Care, Omaha, Nebraska, United States
The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells
- Conditions
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2011-04-27
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 57
- Registration Number
- NCT00609362
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
- Conditions
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 78
- Registration Number
- NCT00577590
- Locations
- 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
Effect of Thiazolidinedione Treatment Vascular Risk Markers
- Conditions
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 25
- Registration Number
- NCT00571506
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Gene Regulation by Thiazolidinediones
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- James Lewis
- Target Recruit Count
- 12
- Registration Number
- NCT00567593
- Locations
- 🇺🇸
University of Pennsylvania Clinical and Translational Research Center, Philadelphia, Pennsylvania, United States
Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2007-11-09
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 27
- Registration Number
- NCT00549874
- Locations
- 🇺🇸
University of Toledo - Health Campus, Toledo, Ohio, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Study Of BRL49653C For The Treatment Of Type 2 Diabetes
- Conditions
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00523913
- Locations
GSK Investigational Site
Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels
- Conditions
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2008-05-09
- Lead Sponsor
- Baskent University
- Registration Number
- NCT00522470
- Locations
- 🇹🇷
Baskent University Hospital Department of Endocrinology, Ankara, Bahçelievler, Turkey
Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?
- Conditions
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2010-07-07
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 160
- Registration Number
- NCT00516880
- Locations
- 🇨🇳
Department of Medicine, Queen Mary Hospital, Hong Kong, China
🇨🇳Department of Medicine, Tung Wah Hospital, Hong Kong, China
The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects
- Conditions
- Interventions
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00511823
- Locations
- 🇺🇸
GSK Investigational Site, Evansville, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.